Please login to the form below

Not currently logged in
Email:
Password:

SMA

This page shows the latest SMA news and features for those working in and with pharma, biotech and healthcare.

Beneluxa: the future of European market access?

Beneluxa: the future of European market access?

Spinraza (nusinersen) is the first drug approved to treat spinal muscular atrophy (SMA), an often-fatal genetic disease, which affects muscle strength and movement, and can strike in infancy or in ... The Netherlands’ health minister Bruno Bruins said

Latest news

More from news
Approximately 7 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • No incentive for a cure No incentive for a cure

    to 12-week course. And Spinraza from Biogen, the first ever disease-modifying treatment for spinal muscular atrophy (SMA), which increases the body’s ability to produce SMN protein critical to.

  • Deal Watch July 2016 Deal Watch July 2016

    In 2014 the partners expanded the agreement for CK-2127107 to include some neuromuscular indications, such as Spinal Muscular Atrophy (SMA).

  • Pharma deals during January 2013 Pharma deals during January 2013

    Repligen announced the signature of an exclusive worldwide licensing agreement with Pfizer to advance Repligen's spinal muscular atrophy (SMA) programme. ... SMA is an orphan neurodegenerative genetic disease that presents early in life.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics